Idorsia Ltd/Fr. IDIA
07:00
09:05
11:10
13:15
15:20
1D1W1MYTD1Y5YMAX
About Idorsia Ltd
Idorsia Ltd is a pharmaceutical company based in Allschwil, Switzerland. The company focuses on the discovery, development, and commercialization of innovative medicines for a variety of therapeutic areas, including cardiovascular, central nervous system, immunological, and orphan diseases. It emerged as an independent entity in 2017 following the demerger from Actelion Ltd after Johnson & Johnson acquired Actelion. Idorsia's development pipeline includes a range of products in clinical trials, highlighting its commitment to addressing unmet medical needs. With a strategic emphasis on expanding its research footprint, Idorsia leverages its expertise in drug discovery and clinical development to secure a stable competitive position in the biopharmaceutical industry.
Ticker
Fr. IDIA
Sector
Primary listing
XSWX
Employees
456
Headquarters
Allschwil, Switzerland
Website
Idorsia Ltd Metrics
BasicAdvanced
CHF 1.6bn
-
-CHF 1.30
-
-
Price and volume
Market cap
CHF 1.6bn
52-week high
CHF 7.56
52-week low
CHF 2.42
Average daily volume
1.5m
Financial strength
Current ratio
0.582
Quick ratio
0.365
Long term debt to equity
-88.993
Total debt to equity
-110.486
Interest coverage (TTM)
-3.99%
Profitability
EBITDA (TTM)
-139.022
Gross margin (TTM)
31.79%
Net profit margin (TTM)
-158.32%
Operating margin (TTM)
-77.52%
Effective tax rate (TTM)
-0.84%
Revenue per employee (TTM)
CHF 440,000
Management effectiveness
Return on assets (TTM)
-20.12%
Return on equity (TTM)
27.07%
Valuation
Price to revenue (TTM)
7.516
Price to book
-1.31
Price to tangible book (TTM)
-1.28
Price to free cash flow (TTM)
-11.869
Free cash flow yield (TTM)
-8.43%
Free cash flow per share (TTM)
-0.518
Growth
Revenue change (TTM)
-8.06%
Earnings per share change (TTM)
83.17%
3-year revenue growth (CAGR)
16.66%
3-year earnings per share growth (CAGR)
-34.41%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.